SCHEMBL8801853

SCHEMBL8801853

O=C1CCCCCC(=O)N1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 6/20 0.80
FKBP5 Q13451 1/20 0.50
ALDH1A1 P00352 3/20 0.47
TRIM24 O15164 2/20 0.47
TRIM33 Q9UPN9 2/20 0.47
OR51E2 Q9H255 1/20 0.45
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
CYP2C19 P33261 2/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
ALOX15 P16050 1/20 0.34
ALOX12 P18054 1/20 0.34
BLM P54132 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912717 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL8567419 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL6049487 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL18301008 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL9716416 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL19350697 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL23028960 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL5909153 1.00 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33
SCHEMBL1335950 0.96
SCHEMBL7888543 0.93 CRBN (0.80) CRBNFKBP5ALDH1A1TRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022097500-A1 PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT 国立大学法人 鹿児島大学 2022-05-12 WO claimed
EP-0530537-B1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-01-08 EP claimed
US-5403843-A Pyrrolopyrimidinyalglutaminate derivatives and their use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-04-04 US claimed
EP-0530537-A1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-03-10 EP claimed
WO-2024020350-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIODISCOVERY, INC. (US) 2024-01-25 WO disclosed
CN-115087445-A Percutaneous absorption preparation 住友制药株式会社 2022-09-20 CN disclosed
WO-2022097500-A1 PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT 国立大学法人 鹿児島大学 2022-05-12 WO disclosed
WO-2022080481-A1 RADIOACTIVE COMPLEXES OF ANTI-HER2 ANTIBODY, AND RADIOPHARMACEUTICAL 日本メジフィジックス株式会社 2022-04-21 WO disclosed
WO-2020012337-A1 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2020-01-16 WO disclosed
US-10434182-B2 Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2019-10-08 US disclosed
US-20070270357-A1 Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. 2007-11-22 US disclosed
US-20070270357-A1 Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. 2007-11-22 US disclosed
EP-0530537-B1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-01-08 EP disclosed
US-5403843-A Pyrrolopyrimidinyalglutaminate derivatives and their use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-04-04 US disclosed
EP-0530537-A1 Condensed pyrimidine derivatives, their production and use as antitumor agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10434182-B2 Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof MRPL38, ALG8, MRPS18A CRBN 2259/4885FKBP5 3631/4885ALDH1A1 1103/4885
US-20070270357-A1 Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same PAICS, MAP2K4, GIPR CRBN 4000/4885FKBP5 365/4885ALDH1A1 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.